Evidence mapPaperPMID 41901326Full record

ReviewPharmaceuticals (Basel, Switzerland)2026

AI-Driven Design of Miniproteins as Potential Allosteric Modulators.

Xin Liu, Yunxiang Sun, Yulong Xia, Huaqiong Li, Zhiqiang Yan

Abstract readReview
In one paragraph

Review in Pharmaceuticals (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Xin LiuZhejiang Key Laboratory of Soft Matter Biomedical Materials, Wenzhou Institute, University of Chinese Academy of Sciences, Wenzhou 325000, China.
Yunxiang SunSchool of Physical Science and Technology, Ningbo University, Ningbo 315211, China.ORCID 0000-0001-9799-7131
Yulong XiaZhejiang Key Laboratory of Soft Matter Biomedical Materials, Wenzhou Institute, University of Chinese Academy of Sciences, Wenzhou 325000, China.ORCID 0009-0007-4126-7931
Huaqiong LiZhejiang Key Laboratory of Soft Matter Biomedical Materials, Wenzhou Institute, University of Chinese Academy of Sciences, Wenzhou 325000, China.ORCID 0000-0002-6151-6479
Zhiqiang YanZhejiang Key Laboratory of Soft Matter Biomedical Materials, Wenzhou Institute, University of Chinese Academy of Sciences, Wenzhou 325000, China.ORCID 0000-0003-3865-3229

Funding

Beijing National Laboratory for Condensed Matter Physics 2023BNLCMPKF009National Natural Science Foundation of China 12474192Zhejiang Key Laboratory of Soft Matter Biomedical Materials 2025ZY01036, 2025E10072Zhejiang Provincial natural Science Foundation of China LZ24A040002
6 · The paper itself

Abstract

Allosteric modulation has emerged as a powerful strategy for achieving superior selectivity and safety in drug discovery and protein function regulation. Unlike highly conserved orthosteric sites, allosteric pockets are structurally diverse and less evolutionarily constrained, making them particularly suitable for modulation by designed miniproteins. Miniproteins can provide extended binding interfaces and high affinity for shallow, dynamic, or cryptic regulatory surfaces that are often inaccessible to small molecules. Recent advances in artificial intelligence (AI) are transforming this field through deep learning-based structure prediction and generative modeling. These AI-driven approaches enable the identification of allosteric hotspots, characterization of conformational ensembles, and de novo design of structured miniprotein binders. They are rapidly expanding the landscape for designing selective modulators across diverse allosteric targets, including GPCRs, receptor tyrosine kinases, nuclear receptors, ion channels, and other protein-protein interaction systems. This review summarizes state-of-the-art AI-driven computational methodologies for designing miniproteins as potential allosteric modulators and discusses their current challenges and future opportunities in allosteric drug discovery.

Indexed as

allosteric modulationartificial intelligencede novo protein designminiprotein design

Identifiers

PMID41901326
PMCPMC13029676

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.